TAKEDA PHARMACEUTICAL CO LTDTAK決算レポート
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...
TAK Q1 2025 Key Financial Metrics
売上高
$4.3M
粗利益
$2.8M
営業利益
$214.1K
純利益
$144.2K
粗利益率
66.5%
営業利益率
5.0%
純利益率
3.4%
前年比成長
N/A
資金フロー
TAKEDA PHARMACEUTICAL CO LTD Q1 2025 財務サマリー
TAKEDA PHARMACEUTICAL CO LTD reported revenue of $4.3M for Q1 2025, with a net profit of $144.2K (3.4% margin). Cost of goods sold was $1.4M, operating expenses totaled $2.6M.
主要財務指標
| 総売上高 | $4.3M |
|---|---|
| 純利益 | $144.2K |
| 粗利益率 | 66.5% |
| 営業利益率 | 5.0% |
| 報告期間 | Q1 2025 |
TAKEDA PHARMACEUTICAL CO LTD 四半期売上・純利益の履歴
TAKEDA PHARMACEUTICAL CO LTD quarterly results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q1 2025 | $4.3M | — | $144.2K | 3.4% |
| Q1 2024 | $4.0M | — | $317.0K | 7.9% |
損益計算書
| Q1 2024 | Q1 2025 | |
|---|---|---|
| 売上高 | $4.0M | $4.3M |
| 前年比成長 | N/A | N/A |
貸借対照表
| Q1 2024 | Q1 2025 | |
|---|---|---|
| 総資産 | $98.21B | $92.61B |
| 総負債 | $50.93B | $47.53B |
| 株主資本 | $47.28B | $45.08B |